8 - The RIPK2 Inhibitor GSK583 Protects Against NOD1-Mediated FFA-Induced Insulin Resistance In Vivo

Shoaib, Falak; Rivers, Sydney L.; Tan, Yongjun; Giacca, Adria

doi:10.1016/j.jcjd.2019.07.015

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibitors of the immune system and immune checkpoint inhibitors are novel molecules with immunoregulatory effects in different pathologies among which several cancers stand out [ 124 , 125 ]. Some examples to mention that are related to diseases in which NOD1 contributes in some way would be the following referenced works: [ 48 ], [ 126 ], and [ 51 ]. Hence, a double immunonutrition–inhibitor(s) strategy (and even more, targeting NOD1) will be helpful in combating certain diseases.…”

Section: A Focus On Future Strategiesmentioning

confidence: 99%

NOD1-Targeted Immunonutrition Approaches: On the Way from Disease to Health

et al. 2021

View full text Add to dashboard Cite

Immunonutrition appears as a field with great potential in modern medicine. Since the immune system can trigger serious pathophysiological disorders, it is essential to study and implement a type of nutrition aimed at improving immune system functioning and reinforcing it individually for each patient. In this sense, the nucleotide-binding oligomerization domain-1 (NOD1), one of the members of the pattern recognition receptors (PRRs) family of innate immunity, has been related to numerous pathologies, such as cancer, diabetes, or cardiovascular diseases. NOD1, which is activated by bacterial-derived peptidoglycans, is known to be present in immune cells and to contribute to inflammation and other important pathways, such as fibrosis, upon recognition of its ligands. Since immunonutrition is a significant developing research area with much to discover, we propose NOD1 as a possible target to consider in this field. It is relevant to understand the cellular and molecular mechanisms that modulate the immune system and involve the activation of NOD1 in the context of immunonutrition and associated pathological conditions. Surgical or pharmacological treatments could clearly benefit from the synergy with specific and personalized nutrition that even considers the health status of each subject.

show abstract